By Abigail Townsend
Date: Wednesday 30 Oct 2024
(Sharecast News) - Shares in Eli Lilly & Co fell sharply on Wednesday, after the US drugs firm missed quarterly forecasts and cut its full-year outlook.
The firm, which makes blockbuster weight-loss drug Zepbound, said third-quarter revenues rose 20% to $11.4bn.
That was driven by a 15% increase in volume...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news